HJB - Your Trusted Biologics CDMO Partner

HJB, CDMO, biologics, HJB Bio, hjbbio, China CDMO, 杭州奕安济世, Just Bio, Just biotherapeutics, HJB bio, HJB China, Hangzhou HJB

HJB - Your Trusted Biologics CDMO Partner

Cn
Company News

27Apr, 2023

HJB Congratulates SynerK on Completion of Subject Administration with Domestic New siRNA Drugs!

On 27th April, SynerK, an innovative biopharmaceutical company focusing on developing RNA-targeted therapeutics, announced that its Phase I clinical trial of the first small interfering RNA (siRNA) product under research has been completed with the first subject enrolled for dosing. Public data shows that this is the first domestic siRNA candidate drug against a specific target, which is involved in the clinical administration and treatment phase in subjects. SynerK owns the completely independent intellectual property right.


21Jul, 2022

The First Batch of siRNA Drug Filled Successfully | HJB Completes High Yield Filling of SynerK's siRNA Formulation.

Small interfering RNA (siRNA) drugs, as a hotspot in the development of small nucleic acid-based drugs, have been widely used for their high gene silencing efficiency, controllable adverse effects, and easy synthesis. Recently, HJB has also embraced the first siRNA formulation filling project, which was commissioned by SynerK, a leading company in siRNA technology, for the development of siRNA formulation prescriptions and filling work. During the project, the two parties cooperated and gave full play to SynerK's experience in the development and production of siRNA formulations and to HJB's experience in the development and filling of injectable liquid formulations. The technical team of HJB overcame many technical difficulties and challenges of siRNA formulation and completed the first batch of filling in one go, with a filling yield as high as 95%.


21Apr, 2022

Leveraging HJB’s highly productive continuous perfusion platform, client’s manufacturing process output was increased by > 8 folds and the process change was recently approved by NMPA.

31Mar, 2022

HJB Congratulates its partner BioneCure for receiving IND approval from U.S.FDA for BIO-106

HJB congratulates its partner BioneCure for receiving IND approval for BIO-106.

30Dec, 2021

HJB congratulates its client on an approval of CMC process change supplemental application filed to Chinese National Medical Products Administration (NMPA) in support of a late phase clinical trial in China.

HJB congratulates its client on an approval of CMC process change supplemental application filed to  NMPA in support of a late phase clinical trial in China.

21Aug, 2021

HJB Congratulates Kanova Biopharma on receiving IND approval for XKH001 from U.S.FDA

HJB Congratulates its partner Kanova Biopharma for receiving IND approval from U.S.FDA for XKH001, a humanized monoclonal antibody for the treatment of autoimmune disease.


06Jul, 2021

HJB Congratulates its partner for receiving IND approval from NMPA

HJB congratulates its partner for receiving IND approval from NMPA.

05Jul, 2021

HJB Congratulates Miracogen for receiving IND acceptance for MRG004A from NMPA

HJB Congratulates its partner Miracogen for receiving IND acceptance from NMPA for MRG004A, an tissue factor-targeted antibody–drug conjugate.